Risk stratification for invasive aspergillosis: early assessment of host susceptibility

References

• Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013–1025
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20: 711–727
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448–1452
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–1297
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348–3459
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–347
   PubMed Web of Science ®Google Scholar
• De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis – has the principle been proven?. N Engl J Med 2007; 356: 409–411
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 2006; 19: 571–576
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824–1833
   PubMed Web of Science ®Google Scholar
• Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601–2614
   PubMed Web of Science ®Google Scholar
• Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med 1998; 338: 1741–1751
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068–1075
   PubMed Web of Science ®Google Scholar
• Muhlemann K, Wenger C, Zenhausern R, Tauber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19: 545–550
   PubMed Web of Science ®Google Scholar
• Nucci M, Spector N, Bueno AP, et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 1997; 24: 575–579
   PubMed Web of Science ®Google Scholar
• Pagano L, Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: 862–870
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345–351
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(Suppl. 1)S49–58
   PubMed Web of Science ®Google Scholar
• Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000; 2: 22–28
   PubMedGoogle Scholar
• Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44–69
   PubMed Web of Science ®Google Scholar
• Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545–548
   PubMed Web of Science ®Google Scholar
• Patterson TF, Peters J, Levine SM, et al. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40: 2217–2220
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9: R191–9
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Greene, RE, Schlamm, HT, Stark, P, , et al. Radiological findings in acute invasive pulmonary aspergillosis: utility and reliability of halo sign and air-crescent sign for diagnosis and treatment of IPA in high-risk patients (abstract O397). In: Program of the 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland, UK; May, 2003.
   Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373–379
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–357
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898–1906
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325–327
   PubMed Web of Science ®Google Scholar
• Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366–2367
   PubMed Web of Science ®Google Scholar
• Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913–916
   PubMed Web of Science ®Google Scholar
• Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448–457
   PubMed Web of Science ®Google Scholar
• Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517–5522
   PubMed Web of Science ®Google Scholar
• Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1– > 3)-beta-D-glucan assay for the diagnosis of invasive fungal infections – a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46: 1864–1870
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205
   PubMed Web of Science ®Google Scholar
• White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479–486
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Gunsilius E, Gastl G, et al. Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses 2005; 48(Suppl. 1)12–17
   PubMed Web of Science ®Google Scholar
• White PL, Archer AE, Barnes RA. Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections. J Clin Microbiol 2005; 43: 2181–2187
   PubMed Web of Science ®Google Scholar
• Verweij PE, Klont RR, Donnelly JP. Validating PCR for detecting invasive aspergillosis. Br J Haematol 2004; 127: 235–236
   PubMed Web of Science ®Google Scholar
• Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006; 42: 487–489
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Lusk E, et al. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol 1985; 3: 1109–1116
   PubMed Web of Science ®Google Scholar
• Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S. Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay. J Infect Dis 1987; 155: 12–27
   PubMed Web of Science ®Google Scholar
• Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495–503
   PubMed Web of Science ®Google Scholar
• Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331–340
   PubMed Web of Science ®Google Scholar